EUROPEAN RESTRICTIONS ON USE OF Rx BRANDNAME FOR OTC SWITCH PRODUCT
This article was originally published in The Tan Sheet
Executive Summary
EUROPEAN RESTRICTIONS ON USE OF Rx BRANDNAME FOR OTC SWITCH PRODUCT poses a threat to the success of the Rx-to-OTC switch movement abroad, Berndt van Till, the incoming president of the European Proprietary Medicines Manufacturers Association (AESGP), suggested June 16 at the group's annual meeting in London. He noted that "restrictions with regard to the use of trademarks" in Europe represent a "barrier" to the "increasing trend to switch ingredients from prescription to nonprescription status."